Inclusion Criteria:

          -  Women age 18 years or older

          -  Confirmed histologic diagnosis of invasive carcinoma of the breast

          -  Pathology confirmation of invasive carcinoma (reported or requested and pending)

          -  ER, PR and HER2 negative on outside or Cedars Sinai biopsy report, where ER and PR
             negative are defined as staining present in ≤10% of invasive cancer cells by IHC, and
             HER2-negative is defined as IHC 0-1+ or FISH <2.0. If ER, PR and HER2 status are not
             reported the results must be requested and pending.

          -  Operable tumor measuring ≥1.0 cm in maximal diameter

          -  Any nodal status

          -  Multifocal and multicentric disease is permitted.

          -  Synchronous bilateral invasive breast cancer is permitted

          -  No indication of distant metastases

          -  Total mastectomy or lumpectomy planned

          -  Tumor amenable to cryoablation as determined by a study radiologist

          -  ECOG performance status score of 0 or 1.

          -  Screening laboratory values must meet the following criteria:

          -  White blood cells (WBCs) ≥ 2000/μL

          -  Absolute neutrophil count (ANC) ≥ 1500/μL

          -  Platelets ≥ 100 x 103/μL ii. Hemoglobin ≥ 9.0 g/dL iii. Serum creatinine ≤ 1.5 x ULN
             or creatinine clearance (CrCl) ≥ 40 mL/min (if using the Cockcroft-Gault formula
             below): Female CrCl = (140 - age in years) x weight in kg x 0.85 72 x serum creatinine
             in mg/dL

          -  AST/ALT ≤ 3 x upper limit of normal (ULN)

          -  Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert's syndrome, who must have total
             bilirubin < 3.0 mg/dL)

          -  No history of known HIV

          -  No history of known active hepatitis B or hepatitis C

          -  Women of childbearing potential** (WOCBP) must use appropriate method(s) of
             contraception. WOCBP should use an adequate method to avoid pregnancy for 23 weeks (30
             days plus the time required for nivolumab and ipilimumab to undergo five half-lives)
             after the last dose of investigational drug

          -  Women of childbearing potential must have a negative serum or urine pregnancy test
             (minimum sensitivity 25 IU/L or equivalent units of HCG)

          -  Women must not be breastfeeding

          -  Willing to adhere to the study visit schedule and the prohibitions and restrictions
             specified in this protocol.

          -  Prior checkpoint blockade administration is permitted with a washout period of 3 weeks

               -  "Women of childbearing potential" is defined as any female who has experienced
                  menarche and who has not undergone surgical sterilization (hysterectomy or
                  bilateral oophorectomy) or who is not postmenopausal. Menopause is defined
                  clinically as 12 months of amenorrhea in a woman over 45 in the absence of other
                  biological or physiological causes.

        Women of childbearing potential (WOCBP) receiving nivolumab and ipilimumab will be
        instructed to adhere to contraception for a period of 23 weeks after the last dose of
        investigational product. Men receiving nivolumab and who are sexually active with WOCBP
        will be instructed to adhere to contraception for a period of 31 weeks after the last dose
        of investigational product. These durations have been calculated using the upper limit of
        the half-life for nivolumab (25 days) and are based on the protocol requirement that WOCBP
        use contraception for 5 half-lives plus 30 days and men who are sexually active with WOCBP
        use contraception for 5 half-lives plus 90 days.

        Exclusion Criteria:

          -  Medical history and concurrent diseases

               -  Has an active autoimmune disease that has required systemic treatment in the past
                  2 years (i.e., with use of disease modifying agents, corticosteroids, or
                  immunosuppressive drugs). Note: Replacement therapy (eg, thyroxine, insulin, or
                  physiologic corticosteroid replacement therapy for adrenal or pituitary
                  insufficiency) is not considered a form of systemic treatment.

               -  Any underlying medical or psychiatric condition, which in the opinion of the
                  investigator, will make the administration of study drug hazardous or obscure the
                  interpretation of AEs, such as a condition associated with frequent or poorly
                  controlled diarrhea.

          -  Prohibited Treatments and/or Therapies

               -  Chronic use of immunosuppressants and/or systemic corticosteroids (used in the
                  management of cancer or non-cancer-related illnesses). Brief periods of steroid
                  use, for example for the management of chemotherapy-associated toxicities, are
                  allowed. The use of corticosteroids on study is allowed for the treatment of
                  immune related adverse events (irAEs) and other medical conditions including
                  adrenal insufficiency.

               -  Any non-oncology live vaccine therapy used for prevention of infectious diseases
                  within 3 weeks prior to first dose of ipilimumab.

               -  Prior investigational agents within 3 weeks prior to ipilimumab/nivolumab